Dr. Ryan Patrick McSpadden, MD

Dr. McSpadden practices at Roswell Park Cancer Institute in Los Angeles, California.

Dr. McSpadden's NPI, 1427324417, was assigned on March 24, 2012. Dr. McSpadden graduated from Sidney Kimmel Medical College at Thomas Jefferson University in 2012. Dr. McSpadden holds New York license 293142.

Dr. McSpadden's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Dr. McSpadden's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Dr. McSpadden is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center. Dmand AI also links Dr. McSpadden to 1 more home health agency, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McSpadden practices, 2 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. McSpadden's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. McSpadden is licensed in New York.

CMS data shows 77 Medicare services from Dr. McSpadden across 3 procedure codes in 2024, for 74 Medicare patients. Medicare paid $2,483 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 74 Medicare patients who saw Dr. McSpadden in 2024. The largest group is 65 to 74, with 34 patients. 75% of them have high cholesterol, and 74% have high blood pressure. Their average risk score is 2.22, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McSpadden's median patient age at 70, with 45% women.

In 2024, Dr. McSpadden wrote 78 Medicare Part D claims for 35 patients. 91% of them were for generic drugs. CMS names the drug for 40 of them, across 3 drugs with 11 or more claims each, at $447 in total drug cost. In 2022, CMS named 17 claims across 1 drug.

Dr. McSpadden accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. McSpadden as offering telehealth. CMS counts 11 procedures of melanoma (skin cancer) excision by Dr. McSpadden, more than 64% of the clinicians it reports for that procedure.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 25 papers to Dr. McSpadden, published from 2016 to 2025. 2021 was the busiest year, with 6. The most frequent topics are Head and Neck Neoplasms, Chemoradiotherapy and Papillomavirus Infections. Dr. McSpadden has published most often in Cancers (Basel). Dr. McSpadden's most frequent co-authors are Vishal Gupta, MD, Wesley L. Hicks, MD and Kimberly E. Wooten, MD.

Dmand AI links Dr. McSpadden to 1 clinical trial. Conditions studied include Mouth Neoplasms and Mouth Diseases.

CMS Open Payments shows 19 general payments to Dr. McSpadden from 10 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. AxoGen paid the most, $590.

Dr. McSpadden graduated from Sidney Kimmel Medical College at Thomas Jefferson University in 2012.